Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
m |
m |
||
| Line 23: | Line 23: | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
| − | [[Category:Hepatocellular | + | [[Category:Hepatocellular carcinoma medications]] |
[[Category:CFDA approved drugs]] | [[Category:CFDA approved drugs]] | ||
Revision as of 00:18, 14 June 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is used
Also known as
- Code name: YN968D1
- Generic name: rivoceranib
- Brand name: Aitan